BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 36358637)

  • 1. Vulvar Malignant Melanoma: A Narrative Review.
    Falcicchio G; Vinci L; Cicinelli E; Loizzi V; Arezzo F; Silvestris E; Resta L; Serio G; Cazzato G; Mastronardi M; Mongelli M; Marinaccio M; Cormio G
    Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Malignant Melanoma of Vulva and Vagina: A Histomorphological Review and Mutation Analysis--A Single-Center Study.
    Rouzbahman M; Kamel-Reid S; Al Habeeb A; Butler M; Dodge J; Laframboise S; Murphy J; Rasty G; Ghazarian D
    J Low Genit Tract Dis; 2015 Oct; 19(4):350-3. PubMed ID: 26225944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progressing Vulvar Melanoma Caused by Instability in cKIT Juxtamembrane Domain: A Case Report and Review of Literature.
    Englert-Golon M; Budny B; Lewandowska M; Burchardt B; Smolarek N; Ziemnicka K; Jagodziński PP; Ruchała M; Grabowska M; Sajdak S
    Curr Oncol; 2022 Apr; 29(5):3130-3137. PubMed ID: 35621644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vulvar and vaginal melanoma: A unique subclass of mucosal melanoma based on a comprehensive molecular analysis of 51 cases compared with 2253 cases of nongynecologic melanoma.
    Hou JY; Baptiste C; Hombalegowda RB; Tergas AI; Feldman R; Jones NL; Chatterjee-Paer S; Bus-Kwolfski A; Wright JD; Burke WM
    Cancer; 2017 Apr; 123(8):1333-1344. PubMed ID: 28026870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NRAS mutations are more prevalent than KIT mutations in melanoma of the female urogenital tract--a study of 24 cases from the Netherlands.
    van Engen-van Grunsven AC; Küsters-Vandevelde HV; De Hullu J; van Duijn LM; Rijntjes J; Bovée JV; Groenen PJ; Blokx WA
    Gynecol Oncol; 2014 Jul; 134(1):10-4. PubMed ID: 24802725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutational Profile in Vulvar, Vaginal, and Urethral Melanomas: Review of 37 Cases With Focus on Primary Tumor Site.
    Zarei S; Voss JS; Jin L; Jenkins SM; Bryce AH; Erickson LA; Bell DA; Kipp BR; Flotte TJ
    Int J Gynecol Pathol; 2020 Nov; 39(6):587-594. PubMed ID: 31567539
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Ren M; Zhang J; Kong Y; Bai Q; Qi P; Zhang L; Wang Q; Zhou X; Chen Y; Zhu X
    Ann Transl Med; 2022 Jan; 10(2):31. PubMed ID: 35282092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma.
    Pracht M; Mogha A; Lespagnol A; Fautrel A; Mouchet N; Le Gall F; Paumier V; Lefeuvre-Plesse C; Rioux-Leclerc N; Mosser J; Oger E; Adamski H; Galibert MD; Lesimple T
    J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1530-8. PubMed ID: 25623140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vulvar malignant melanoma: Pathogenesis, clinical behaviour and management: Review of the literature.
    Boer FL; Ten Eikelder MLG; Kapiteijn EH; Creutzberg CL; Galaal K; van Poelgeest MIE
    Cancer Treat Rev; 2019 Feb; 73():91-103. PubMed ID: 30685613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutations.
    Chraybi M; Abd Alsamad I; Copie-Bergman C; Baia M; André J; Dumaz N; Ortonne N
    Hum Pathol; 2013 Sep; 44(9):1902-11. PubMed ID: 23664541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple metastases after surgery for a rare vulvar malignant melanoma combined with immunotherapy: a case report.
    Li W; Song J; Sun Y; Cui Z
    J Int Med Res; 2020 Nov; 48(11):300060520965398. PubMed ID: 33203293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of In Vivo Reflectance Confocal Microscopy in the Analysis of Melanocytic Lesions.
    Serban ED; Farnetani F; Pellacani G; Constantin MM
    Acta Dermatovenerol Croat; 2018 Apr; 26(1):64-67. PubMed ID: 29782304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The molecular profile of metastatic melanoma in Australia.
    Lyle M; Haydu LE; Menzies AM; Thompson JF; Saw RP; Spillane AJ; Kefford RF; Mann GJ; Cooper WA; Yu B; Scolyer RA; O'Toole SA; Long GV
    Pathology; 2016 Feb; 48(2):188-93. PubMed ID: 27020391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gynecologic melanomas: A clinicopathologic and molecular analysis.
    Udager AM; Frisch NK; Hong LJ; Stasenko M; Johnston CM; Liu JR; Chan MP; Harms PW; Fullen DR; Orsini A; Thomas DG; Lowe L; Patel RM
    Gynecol Oncol; 2017 Nov; 147(2):351-357. PubMed ID: 28844540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KIT pathway alterations in mucosal melanomas of the vulva and other sites.
    Omholt K; Grafström E; Kanter-Lewensohn L; Hansson J; Ragnarsson-Olding BK
    Clin Cancer Res; 2011 Jun; 17(12):3933-42. PubMed ID: 21680547
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Ponti G; Manfredini M; Greco S; Pellacani G; Depenni R; Tomasi A; Maccaferri M; Cascinu S
    Anticancer Res; 2017 Dec; 37(12):7043-7048. PubMed ID: 29187493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF, NRAS, KIT, TERT, GNAQ/GNA11 mutation profile analysis of head and neck mucosal melanomas: a study of 42 cases.
    Öztürk Sari Ş; Yilmaz İ; Taşkin OÇ; Narli G; Şen F; Çomoğlu Ş; Firat P; Bİlgİç B; Yilmazbayhan D; Özlük Y; Büyükbabanİ N
    Pathology; 2017 Jan; 49(1):55-61. PubMed ID: 27914687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vulvar melanoma: relevant aspects in therapeutic management.
    Campaner AB; Fernandes GL; Cardoso FA; Veasey JV
    An Bras Dermatol; 2017; 92(3):398-400. PubMed ID: 29186258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma.
    Siroy AE; Boland GM; Milton DR; Roszik J; Frankian S; Malke J; Haydu L; Prieto VG; Tetzlaff M; Ivan D; Wang WL; Torres-Cabala C; Curry J; Roy-Chowdhuri S; Broaddus R; Rashid A; Stewart J; Gershenwald JE; Amaria RN; Patel SP; Papadopoulos NE; Bedikian A; Hwu WJ; Hwu P; Diab A; Woodman SE; Aldape KD; Luthra R; Patel KP; Shaw KR; Mills GB; Mendelsohn J; Meric-Bernstam F; Kim KB; Routbort MJ; Lazar AJ; Davies MA
    J Invest Dermatol; 2015 Feb; 135(2):508-515. PubMed ID: 25148578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma.
    Zebary A; Omholt K; Vassilaki I; Höiom V; Lindén D; Viberg L; Kanter-Lewensohn L; Johansson CH; Hansson J
    J Dermatol Sci; 2013 Dec; 72(3):284-9. PubMed ID: 23993026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.